56results about How to "Enhance antigen presentation" patented technology

The invention relates generally to the treatment and prevention of human cancer and viral diseases. More specifically, this invention relates to development of a new generation of vaccines that rely on eliciting cellular immune responses, specifically induction of cytotoxic T lymphocytes (CTL), against cancer cells and virus-infected cells via administration of a vaccine comprising a fusion peptide or a modified peptide. Such a fusion peptide is composed of an insertion signal sequence and a peptide derived from a tumor antigen or a viral antigen, which improves antigen presentation and induces CTL with higher efficiency against cancer cells and virus-infected cells. An exemplary antigen utilized in the invention is HER2 / neu. The peptides peptide vaccines of the invention are derived from the antigens PRAME, OFA / iLRP, STEAP and SURVIVIN.

Compositions and methods of producing vaccines, including methods wherein whole organism vaccines are provided with limited replication abilities, thereby increasing vaccine safety and efficacy, through the use of non-natural, unnatural, or non-naturally encoded amino acids.

Compositions and methods of producing vaccines, including methods wherein whole organism vaccines are provided with limited replication abilities, thereby increasing vaccine safety and efficacy, through the use of non-natural, unnatural, or non-naturally encoded amino acids.

Provided is a method of cross-priming CD8+ T cells to antigens using Dendritic Cells cultured in the presence of a type I Interferon and GM-CSF, and vaccines and methods of vaccination comprising said Dendritic Cells.

The invention relates to a recombinant adeno-associated virus. The recombinant adeno-associated virus is formed by inserting a tumor antigen gene into a shuttle expression vector pAAV-MCS. The invention also provides a construction method and an application of the recombinant adeno-associated virus. According to the invention, the recombinant adeno-associated virus carrying a tumor-associated antigen gene is utilized for infecting DC cells and expresses tumor-associated antigen protein in the DC cells, and a PD-1 gene is also combined for silencing CTL cells in the application method of the recombinant adeno-associated virus.

The present invention relates to various pharmaceutical compositions that can be used as active or passive vaccines for the treatment or prevention of fungal disease. Methods for prevention and treatment of infectious and allergic fungal diseases in subjects using the pharmaceutical compositions of the present invention are also disclosed.

Whole-cell vaccines and methods for their use in producing protective immune responses in vertebrate hosts subsequently exposed to pathogenic bacteria. The present invention involves a method of enhancing antigen presentation by intracellular bacteria in a manner that improves vaccine efficacy. After identifying an enzyme that has an anti-apoptotic effect upon host cells infected by an intracellular microbe, the activity of the enzyme is reduced, thereby modifying the microbe so that it increases immunogenicity. Also, the present invention provides a method of incrementally modifying enzyme activity to produce incrementally attenuated mutants of the microbe from which an effective vaccine candidate can be selected.

The invention discloses a method for preparing HPV (human papillomavirus) antigen specific CTL (cytotoxic T lymphocyte) and particularly discloses a preparation method of HLA-A2402 restrictive anti-HPV antigen specific CTL. According to the method, a peripheral blood mononuclear cell is collected through single blood collection or venous blood collection, the antigen presentation function of B cells is enhanced with CpG ODN 2395, the B cells supporting HLA-A2402 restrictive HPV antigen peptide are used for stimulating the peripheral blood mononuclear cell, rhIL-2, rhIL-7, rhIL-15 and rhIL-21 are jointly used to promote growth of the T cell. The target CTL prepared with the method has the characteristics that preparation is simple, the preparation cycle is short, the cost is low, the multiplication capacity and the killing activity are high, the cell viability is high and the like, and can be used for immunotherapy of HPV infection related diseases including cervical cancer.

The invention relates to a construction, amplification and purification method of a porcine CD40L / GMCSF / PCV2Cap recombinant adenovirus. The method comprises the steps of: S1. connecting CD40L, GM-CSF and Cap to a vector pUC57 in order, and naming the product as pUC-CD40L-Cap-GMCSF; S2. connecting CD40L, Cap and GM-CSF to pShuttle-CMV, converting DH5a, conducting bacteria picking, bacteria shaking and plasmid extraction, and naming the product as PS-CD40L-Cap-GMCSF; S3. linearizing the constructed PS-CD40L-Cap-GMCSF, then conducting electric transformation on BJ5183 with the linearized PS-CD40L-Cap-GMCSF and skeleton plasmid pAdEasy-1, and then carrying out bacteria picking, bacteria shaking and plasmid extraction, and performing single enzyme digestion identification; S4. when the identification result is right, using a kit to extract plasmid, transfecting HEK293A cell, when cell lesion appears, collecting cells, performing centrifugation, then resuspending the precipitate in autoclaving PBS; S5. carrying out repeated freezing and thawing, performing centrifugation to extract the supernatant, thus obtaining recombinant adenovirus; 6. amplifying the obtained recombinant adenovirus; and 7. purifying the recombinant adenovirus. The method provided by the invention for the first time adds porcine tumor necrosis factor related activation protein gen and porcine granulocyte-macrophage colony stimulating factor into the adenovirus vector simultaneously to improve expression of the PCV2 Cap recombinant adenovirus immunogenicity.

The invention provides a construction method of a humanized immune system mouse with myeloid immune cells. The construction method is characterized by comprising the step of artificially supplementingexogenous cytokines GM-CSF, IL-3 and SCF. By the construction method, the humanized immune system mouse is further perfected, so that the humanized immune system mouse has a more complete immune system. The antigen presentation capability of the humanized immune system mouse is greatly improved by promoting development of myeloid immune cell subgroups including mononuclear-macrophages, DC cells and the like. On the basis of an original immune system mainly containing T and B lymphocytes, the capabilities of generating antibodies, performing specific cytotoxic killing and the like are increased. After the exogenous human cytokines are supplemented, the development level of the myeloid immune cells in the humanized immune system mouse is greatly improved, the level of the corresponding immune cell subgroups in normal human peripheral blood is achieved, and the corresponding functions are fulfilled.

The invention relates to a health care method for improving vaccine immunity effect and reducing immunity stress response of livestock and poultry, which is an immunity-enhancing health care method implemented during vaccine inoculation of livestock and poultry. The method is specifically as follows: for each time of vaccine inoculation, the medicament taking method comprises the following specific steps of: taking a first medicament one day before immunization; taking a second medicament on the day of immunization; and taking a third medicament three days after immunization. According to the invention, the body immunity and disease resistance of livestock and poultry can be obviously enhanced, the vaccine immunization effect can be enhanced, the immunization success is ensured, and the vaccine stress response is reduced.

The invention discloses a culture solution and a culture method of DC cells. The culture solution of the DC cells is added in batches according to the growth condition of the DC cells, namely an adherent cell culture solution, a subsequent first supplemented DC cell culture solution and a subsequent second supplemented DC cell culture solution, wherein the adherent cell culture solution comprises a serum-free DC culture medium, GM-SCF and IL-13; the subsequent first supplemented DC cell culture solution comprises a serum-free DC culture medium, GM-CSF, IL-4, an anti-CD 83 antibody and autoserum with the concentration of 1%; and the subsequent second supplemented DC cell culture solution comprises TNF-a, vitamin B12 and nicotinamide. By applying the culture solution and the culture method disclosed by the invention, the DC cells are cultured to be mature in a short time, the DC cells can be mature in only 3 days, the number and purity of the cells are high, the antigen presentation ability of the DC cells is strong, and the culture solution has an excellent anti-tumor effect.

An immunity enhancing therapeutic vaccine includes a gene vector based on recombinant adenovirus and three elements: 1) an HPV antigen including the E6 and E7 multivalent fusion proteins of HPV types 16 and 18, 2) an immunologic adjuvant protein fused with said antigen, which protein may be a heat shock protein (HSP) of Mycobacterium tuberculosis, and 3) an immunostimulant, which may be granulocyte-macrophage colony stimulating factor (GM-CSF). The vaccine is used for the treatment of human papilloma virus infections and related diseases.

The invention provides a method for inducing DC-CIK by utilizing muramyl dipeptide, that is to say, the muramyl dipeptide is added into a CIK or DC-CIK culture solution to induce proliferation and differentiation of CIK or DC-CIK cells, so as to improve the tumor-killing activity of the CIK or DC-CIK cells. The method comprises the following steps: peripheral blood collection, tumor antigen acquisition, mononuclear cell separation, mononuclear cell collection, mononuclear cell washing, MDP-DC-CIK cell induction, and culture. MDP-DC-CIK cells introduced and cultured by the method are detected by a flow cytometry, the ratio of CD3+CD56+ non-MHC restricted NKT cells is found to be up to 80% or more; and at the same time, the activity of tumor killer cells is much higher than that of DC-CIK cells by conventional induction culture, and a laboratory test result of the tumor-killing percentage reaches 99% or more.

Provided herein is a combination comprising an HDAC inhibitor and an IMiD for increasing interferon regulated gene expression or decreasing c-MYC gene expression in a cancer cell or tumor in a subject in need thereof. Increasing interferon regulated gene expression may result in increased recognition of tumors by innate or adaptive immune system and an increase in programmed cell death (apoptosis) gene expression, increasing apoptosis in cancer cells and tumors. The cells can be multiple myeloma cells or diffuse large B-cell lymphoma cells. Also provided are methods for treating myelodysplastic syndromes / acute myeloid leukemia (MDS / AML) or pathogen infections in a subject in need thereof comprising administering to the subject an effective amount of HDAC inhibitor and an IMiD. The HDAC inhibitor can be an HDAC6-selective inhibitor.